Abstract：Objective To investigate the effect of Activating Qi and Resolving Stagnation Formula in the treatment of post-stroke depression. Methods One hundred and eight cases of patients with post-stroke depression in Dongguan People′s Hospital from September 2014 to May 2016 were selected and randomly divided into two groups by random number table method, with 54 cases in each group. The control group received Flupentixol and Melitracen Tablets, the observation group received Activating Qi and Resolving Stagnation Formula, both groups were treated for 8 weeks. The scores of Hamilton depression scale (HAMD), national institute of health stroke scale (NIHSS) and activities of daily living (ADL) were evaluated. The levels of neurotransmitter and neurocytokines were determined, and the clinical efficacy between the two groups was compared. Results Compared with before treatment, the scores of HAMD, NIHSS in the two groups after treatment were decreased, ADL scores were increased, the levels of serum 5-hydroxy tryptamine (5-HT) , noradrenaline (NE), dopamine (DA) were increased, the levels of 5-hydroxy indole acetic acid (5-HIAA) were decreased, and the levels of serum brain derived neurotrophic factor (BDNF), nerve growth factor (NGF) were increased (P ＜ 0.05). Compared with the control group, the scores of HAMD, NIHSS in the observation group after treatment were decreased, ADL scores were increased, the levels of serum 5-HT, NE and DA were increased, the levels of 5-HIAA were decreased, and the levels of serum BDNF and NGF were increased, the differences were statistically significant (P ＜ 0.05). The total effective rate of the control group (75.93%) was lower than that of observation group (90.74%), the difference was statistically significant (P ＜ 0.05). Conclusion Activating Qi and Resolving Stagnation Formula can relieve depression in patients with post-stroke depression, improve the ability of daily living and the neurotransmitter metabolism, which is worthy to be widely promoted.
庄雪. 行气解郁方治疗卒中后抑郁的临床研究[J]. 中国医药导报, 2018, 15(3): 145-149.
ZHUANG Xue. Clinical study of Activating Qi and Resolving Stagnation Formula in the treatment of post-stroke depression. 中国医药导报, 2018, 15(3): 145-149.
[1] Tanaka Y，Suzuki K，Iijima T，et al. Efficacy and Safety of Citalopram Combined with Buspirone in Treatment of Patients with Post-stroke Depression [J]. Revue Francaise D Allergologie，2015，55（3）：231-231.
[2] 杜渊，白雪，杨思进，等.柴芍六君子汤加减联合金双歧辅助治疗脑卒中后抑郁患者36例临床观察[J].中医杂志，2016，57（11）：946-948.
[3] 贾春霞，徐清照，杜月光，等.中医理气活血解郁法对比西医百忧解片治疗老年脑卒中后抑郁的临床研究[J].中华中医药学刊，2014，20（11）：2585-2588.
[4] 聂容荣，江伟，卢妃萍，等.加味补阳还五汤治疗缺血性脑卒中后抑郁症的临床研究[J].中成药，2016，38（4）：958-960.
[5] 胡丹，盛蕾.加味柴胡疏肝颗粒辅助治疗缺血性脑卒中后抑郁的疗效观察[J].中草药，2016，47（21）：3866-3870.
[6] 王少石，周新雨，朱春燕.卒中后抑郁临床实践的中国专家共识[J].中国卒中杂志，2016，11（8）：685-693.
[7] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[8] Towfighi A，Ovbiagele B，El Husseini N，et al. Poststroke Depression：A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association [J]. Stroke，2017，48（2）：e30-e43.
[9] Winstein CJ，Stein J，Arena R，et al. Guidelines for Adult Stroke Rehabilitation and Recovery：A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association [J]. Stroke，2016，47（6）：e98.
[10] Broen MP，Moonen AJ，Kuijf ML，et al. Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease [J]. Parkinsonism Related Disord，2015，21（2）：142-146.
[11] Dunning K. National Institutes of Health Stroke Scale [J]. Encyclopedia of Clinical Neuropsychology，2011，9（1）：1714-1715.
[12] Qafarizadeh F，Farhadian M，Bozorgi AAJ，et al. Effect of Gait Retraining on Balance，Activities of Daily Living，Quality of Life and Depression in Stroke patients [J]. Cell，2015，79（5）：743-746.
[13] 贾春霞，徐清照，朱志红，等.理气活血解郁方合认知行为疗法治疗老年脑卒中后抑郁的临床研究[J].中华中医药学刊，2013，31（4）：733-736.
[14] 童叶青，王峰，郭慧，等.卒中后抑郁研究进展[J].老年医学与保健，2015，21（1）：55-58.
[15] 李辉，刘丽娟，张会凯.柴附解郁方联合米氮平治疗肝郁气结型抑郁症的临床研究[J].中西医结合心脑血管病杂志，2015，13（8）：1027-1029.
[16] 王彦云，郑军，李多娇，等.开心解郁汤对血管性抑郁大鼠行为的影响[J].北京中医药大学学报，2010，33（2）：98-102.
[17] 陈国胜，孙云廷.痰瘀致病论对脑卒中后抑郁临床辨证论治的影响[J].中国中医急症，2015，24（1）：72-73.
[18] 王联生，潘菊华.香附及其复方抗抑郁应用[J].时珍国医国药，2017，28（5）：1180-1182.
[19] 赵瑞珍，唐启盛，田青，等.颐脑解郁方对脑出血后抑郁大鼠核磁共振波谱的干预作用[J].中国科学：生命科学，2016，46（8）：959.
[20] 王海丽，廖梅蓉.认知行为疗法联合草酸艾司西酞普兰治疗抑郁症临床观察[J].现代医院，2016，16（5）：714-716.
[21] 杨卫华，董介正，李秀荣.氟西汀治疗脑卒中后抑郁的疗效及对认知功能的影响[J].中国现代医生，2016，54（34）：24-26，30.
[22] 薛海兵，覃佐爱，吴清明，等.电针“四关”对缺血性脑卒中后抑郁大鼠海马组织单胺类神经递质含量的影响[J].国际中医中药杂志，2015，37（1）：65-69.
[23] 李辉，张会凯，刘丽娟.柴附解郁方联合米氮平对肝郁气结型抑郁症患者血清NE、5-HT水平的影响[J].河南中医，2016，36（11）：1984-1986.
[24] 吴赛珍，陈力宇，孙乐球，等.丁苯酞对卒中后抑郁的疗效观察及作用机制研究[J].中国现代医生，2016，54（36）：117-120.
[25] 李知莲，吴慧芳.艾地苯醌治疗对缺血性脑卒中后抑郁患者血清学指标的影响[J].海南医学院学报，2015，21（2）：262-264.
2018, Vol. 15 
京公网安备 11010502046598号